CCR2 and ovarian carcinoma: Investigate how SLFN11 affects the response to immunotherapy by regulating immune cell infiltration (such as T cells and macrophages) or cytokine secretion (such as the CCL2/CCR2 axis), especially in hepatocellular carcinoma (74) and ovarian cancer (12).